BETHESDA, Md.–(BUSINESS WIRE)–Aledade PBC, a physician‑led, national leader in value‑based care, has been named a 2026 Remote Work Top Workplace by TopWorkplaces.com.
Month: September 2026
LONDON–(BUSINESS WIRE)– As Agent Bank, please be advised of the following rate determined on: 9/21/2026 Issue ¦ Westpac Banking Corporation – Series 2025-C2 GBP 1,250,000,000 FRN due September 2030 ISIN Number ¦ XS3200096777 ISIN Reference ¦ XS3231291009 Issue Nomin GBP ¦ 1250000000 Period ¦ 6/26/2026 to 9/28/2026 Payment Date 9/28/2026 Number of Days ¦ 94 Rate ¦ 4.3482 Denomination GBP ¦ 1000 ¦ 1250000000 ¦ Amount Payable per Denomination ¦ 11.2 ¦ 13997630.14 ¦ B
LIESTAL, Suisse–(BUSINESS WIRE)–Curatis Holding AG (SIX : CURN, « Curatis ») annonce un chiffre d’affaires net issu de la vente de biens et de services de 7,9 millions CHF pour le premier semestre 2026, en hausse de 51 % (S1 2025 : 5,2 millions CHF), tandis que la perte de la période s’est réduite à -0,4 million CHF (S1 2025 : -1,2 million CHF) et que la trésorerie et les équivalents de trésorerie ont augmenté pour atteindre 3,6 millions CHF (31 décembre 2025 : 1,9 million CHF). Curatis a éga
NEW YORK–(BUSINESS WIRE)—- $CCOI #CCOI–Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cogent Communications Holdings, Inc. (““Cogent” or the “Company”) (NASDAQ: CCOI) and reminds investors of the September 21, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California an
CHICAGO–(BUSINESS WIRE)–The Mather Group, LLC (TMG), a $17 billion leading wealth management firm serving high-net-worth individuals and families nationwide, today announced that it has been ranked No. 41 on Barron’s 2026 Top 100 RIA Firms, placing TMG among the top 50 registered investment advisory firms nationally.The recognition comes as TMG continues to thoughtfully expand its national presence and capabilities while maintaining a planning-led approach centered on helping clients navigate
LIESTAL, Schweiz–(BUSINESS WIRE)–Die Curatis Holding AG (SIX:CURN, „Curatis“) meldet für das erste Halbjahr 2026 einen Nettoumsatz aus Waren und Dienstleistungen von 7,9 Mio. CHF, ein Plus von 51 % (1. Halbjahr 2025: 5,2 Mio. CHF). Der Periodenverlust verringerte sich auf -0,4 Mio. CHF (1. Halbjahr 2025: -1,2 Mio. CHF), während die liquiden Mittel auf 3,6 Mio. CHF stiegen (31. Dezember 2025: 1,9 Mio. CHF). Außerdem erzielte Curatis auf mehreren Ebenen Fortschritte mit seinem Corticorelin-Prog
Company announcement No. 49 / 2026
Zealand Pharma – Transactions related to share buy-back program (week 38, 2026)
Copenhagen, Denmark, September 21, 2026 – Zealand Pharma A/S (“the Company” or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the “Program”) for week 38 (September 14 – September 18, 2026).
The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, “MAR”) and Commission Delegated Regulation (EU) 2016/1052 (the “Safe Harbour Regulation”). Reference is made to company announcement no. 15 / 2026 dated May 7, 2026, which sets out the full terms of the Program. Under the Program, Zealand Pharma may repurchase shares for a total consideration of up to DKK 1.3 billion. The maximum number of shares that may be acquired under the Program is 7,152,557, and the Program commenced on May 7, 2026, and will be completed no later than October 31, 2026. The Company has appointed Danske Bank as lead manager for the Program. Danske Bank will make its own trading decisions independently of, and without influence from, the Company.
Transactions executed in week 38
The following transactions have been executed on Nasdaq Copenhagen (XCSE) under the Program during week 38 (September 14, 2026 – September 18, 2026):
| Date | Number of shares | Average purchase price (DKK) | Transaction value (DKK) |
| Accumulated as per latest announcement | 3,300,000 | 998,344,370 | |
| 14/09/2026 | 70,000 | 282.39 | 19,767,300 |
| 15/09/2026 | 70,000 | 277.75 | 19,442,500 |
| 16/09/2026 | 70,000 | 274.13 | 19,189,100 |
| 17/09/2026 | 60,000 | 276.72 | 16,603,200 |
| 18/09/2026 | 55,000 | 283.64 | 15,600,200 |
| Accumulated (W38) | 325,000 | 90,602,300 | |
| Total accumulated under the Program |
3,625,000 | 1,088,946,670 |
Treasury shares and share capital
Following the transactions described above, Zealand Pharma holds a total of 4,495,842 treasury shares, corresponding to approximately 6,28% of the Company’s share capital.
The total number of shares in Zealand Pharma is 71,610,005, each with a nominal value of DKK 1.
Additional information
Detailed information on each transaction executed under the Program is available in the appendix to this company announcement.
About Zealand Pharma
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health. To date, more than 10 Zealand Pharma invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization. Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston, Massachusetts. Learn more at www.zealandpharma.com.
Contacts
Eric Rojas (Investors)
Vice President, Head of Investor Relations
Zealand Pharma
Email: erojas@zealandpharma.com
Neshat Anis Ahmadi (Investors)
Investor Relations Manager
Zealand Pharma
Email: neahmadi@zealandpharma.com
Rachel James-Owens (Media)
Vice President, Corporate Communications and Media Relations
Zealand Pharma
Email: rjamesowens@zealandpharma.com
Andreas Hylleberg Mølleskov (Media)
Director, External Communications
Zealand Pharma
Email: ahylleberg@zealandpharma.com
Attachment
GREENWICH, Conn., Sept. 21, 2026 (GLOBE NEWSWIRE) — XPO (NYSE: XPO), a leading provider of freight transportation in North America, has been named to the 2027 FreightTech 100 list by FreightWaves, a global provider of supply chain market intelligence. XPO has been included on the FreightTech 100 every year since the inception of the list, which recognizes the most innovative companies in the freight transportation industry.
XPO’s operations are powered by cloud-based proprietary technologies that enable agility, efficiency and speed. Over the past year, the company has continued to introduce new AI applications while scaling proven tools across its network. These advances include broader deployment of AI-powered pickup-and-delivery route optimization, as well as new load photo analysis technology that gives frontline employees real-time feedback on trailer load quality.
Jay Silberkleit, chief information officer of XPO, said, “Being named to the FreightTech 100 reflects our industry-leading technology and culture of continuous innovation. We’re building proprietary solutions that deliver actionable insights to our employees, helping us move freight more efficiently and deliver better service for our customers.”
The FreightTech 100 list was selected from hundreds of nominations by a panel of FreightWaves journalists, market analysts and researchers. XPO is one of only 11 companies that have made the list every year since 2020.
About XPO
XPO, Inc. (NYSE: XPO) is a leader in asset-based less-than-truckload (LTL) freight transportation in North America. The company’s customer-focused organization efficiently moves 16 billion pounds of freight per year, enabled by its proprietary technology. XPO serves 55,000 customers with 586 locations and 38,000 employees in North America and Europe, and is headquartered in Greenwich, Conn., USA. Visit xpo.com for more information, and connect with XPO on LinkedIn, Facebook, X, Instagram and YouTube.
Investor Contact
Brian Scasserra
+1-617-607-6429
brian.scasserra@xpo.com
Media Contact
Cole Horton
+1 203-609-6004
cole.horton@xpo.com
Selection comes as campus celebrates 60 years serving the Dallas-Fort Worth Area
Lincoln Tech’s Grand Prairie campus has been part of the Dallas-Fort Worth education community since 1966
Lincoln Tech focuses on student success
Parsippany, NJ, Sept. 21, 2026 (GLOBE NEWSWIRE) — Lincoln Educational Services Corporation (NASDAQ: LINC), a national leader in specialized technical training, has announced its Grand Prairie, TX campus has been selected as a School of Excellence by the Accrediting Commission of Career Schools and Colleges (ACCSC). Each year ACCSC recognizes schools across the country that meet its highest standards for delivering quality career-focused education and training to students.
Lincoln Tech’s Grand Prairie campus has been part of the Dallas-Fort Worth’s education community since 1966. Career training is currently available for the Auto and Diesel Service, Electrical, HVAC-R and Welding industries – fields which are projected to add 2.6 million jobs across the country by 2034*. The campus is also home to the Hussmann Refrigeration TechX training center.
“We are honored to be selected by ACCSC for this award,” says Scott Shaw, Lincoln Tech’s President and CEO. “This demonstrates our commitment to student success while helping employers build stronger, competitive workforces. We’re grateful to ACCSC for recognizing our efforts, and we look forward to continuing to meet and exceed their standards and the expectations of our students and employer partners.”
“ACCSC is pleased to recognize Lincoln Tech in Grand Prairie, Texas as a School of Excellence,” says Dr. Michale McComis, ACCSC’s Executive Director. “This award underscores the school’s efforts to help students achieve high-quality skills and to make a difference in their lives in and in their community. Excellence matters and it does not come easily – that is why we spotlight it.”
ACCSC accredits 545 institutions throughout the United States and Puerto Rico, as well as internationally in Europe and Asia. Lincoln Tech’s Grand Prairie campus is one of just 18 schools to be recognized for this award.
* Career growth projections can be found at onetonline.org for the years 2024-2034 and are current as of August 25, 2026.
###
About Lincoln Educational Services Corporation
Lincoln Educational Services Corporation is a leading provider of diversified career-oriented post-secondary education. Lincoln offers recent high school graduates and working adults career-oriented programs in four principal areas of study: transportation, healthcare, skilled trades, and information technology. Lincoln has provided the workforce with skilled technicians since its inception in 1946.
Lincoln currently operates 22 campuses in 12 states under 3 brands: Lincoln College of Technology, Lincoln Technical Institute, and Nashville Auto-Diesel College.
For more information, go to lincolntech.edu.
Attachments
- Lincoln Tech’s Grand Prairie campus has been part of the Dallas-Fort Worth education community since 1966
- Lincoln Tech focuses on student success
CONTACT: Scott Watkins, VP Marketing Lincoln Tech 973.766.9656 Swatkins@lincolntech.edu
NANJING, China, Sept. 21, 2026 (GLOBE NEWSWIRE) — Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that its pivotal registrational Phase IIb study of opamtistomig (LBL-024), the Company’s proprietary PD-L1/4-1BB bispecific antibody, as monotherapy for patients with advanced extrapulmonary neuroendocrine carcinoma (EP-NEC), has been selected as a Late-Breaking Abstract (LBA) and Proffered Paper presentation at the ESMO Congress 2026.
The selection highlights the clinical importance and scientific interest of the study and further demonstrates the growing international recognition of opamtistomig and Leads Biolabs’ clinical development capabilities. Notably, three Company-sponsored studies have been selected for Proffered Paper presentations at ESMO 2026, spanning EP-NEC and multiple myeloma.
Pivotal Phase IIb Study of Opamtistomig in Advanced EP-NEC Selected as Late-Breaking Abstract
The pivotal, registrational Phase IIb study is evaluating the efficacy and safety of opamtistomig monotherapy in patients with advanced EP-NEC who have received at least two prior lines of systemic therapy. The study generated key clinical data supporting the Company’s recent New Drug Application (NDA) submission to the National Medical Products Administration (NMPA).
Study Title:
Opamtistomig (LBL-024) monotherapy in advanced extra-pulmonary neuroendocrine carcinoma (EP-NEC) after >2 prior lines of therapies: results from a pivotal, registrational Phase IIb study of a novel PD-L1×4-1BB bispecific antibody
Presentation Type: Late-Breaking Abstract (LBA) / Proffered Paper
Principal Investigator: Professor Lin Shen, Peking University Cancer Hospital
Presenter: Dr. Ming Lu, Peking University Cancer Hospital
Presentation Time: 10:15-10:25, local time, 26 October
The ESMO 2026 LBA presentation will provide the pivotal clinical results from this study, offering further insights into the efficacy and safety profile of opamtistomig in this high unmet-need patient population.
Three Proffered Paper Presentations at ESMO 2026
In addition to the EP-NEC pivotal study, two other Leads Biolabs studies have been selected for Proffered Paper presentations at ESMO 2026:
- A pivotal registrational Phase IIb study of opamtistomig monotherapy in advanced EP-NEC, also selected as a Late-Breaking Abstract;
- A Phase Ib/II study of opamtistomig in combination with chemotherapy as first-line treatment for advanced EP-NEC; and
- A Phase I study of LBL-034 in patients with relapsed/refractory multiple myeloma (RRMM).
The selection of three studies for Proffered Paper presentations underscores the breadth of Leads Biolabs’ clinical development portfolio and its continued focus on advancing innovative therapies across areas of significant unmet medical need.
Broad ESMO 2026 Representation Across the Pipeline
In addition, four other Company-sponsored studies have been selected for poster presentations at ESMO 2026, covering clinical research of opamtistomig in biliary tract cancer (BTC), a mechanistic study in microsatellite-stable colorectal cancer (MSS CRC), and several meta-analyses.
Together, these presentations span clinical development, translational research and evidence synthesis, reflecting the breadth of Leads Biolabs’ oncology research portfolio and its commitment to generating high-quality clinical and scientific evidence.
Executive Commentary
Dr. Charles Cai, Chief Medical Officer of Leads Biolabs, said: “The selection of our pivotal study of opamtistomig in advanced EP-NEC as a Late-Breaking Abstract at ESMO 2026 represents important recognition of the scientific and clinical interest in this program and the significant unmet need faced by patients with advanced EP-NEC. The selection of three Company-sponsored studies for Proffered Paper presentations further reflects the strength and breadth of our clinical development portfolio.
Opamtistomig is a cornerstone of our IO 2.0 strategy, and we are advancing its development across multiple tumor types and treatment settings. We remain focused on translating our differentiated PD-L1/4-1BB bispecific antibody approach into meaningful clinical benefits for patients and on advancing innovative treatment options for patients with cancer worldwide.”
About EP-NEC
Neuroendocrine carcinoma (NEC) is a highly malignant, immunologically “cold” tumor, accounting for approximately 10% to 20% of neuroendocrine neoplasms. NEC may arise in various organs, including the lung, gastrointestinal tract and bladder. NEC can be classified into pulmonary NEC and extrapulmonary NEC. EP-NEC shares the highly aggressive and metastatic characteristics of small cell lung cancer (SCLC), progresses rapidly, and most patients with NEC present with advanced-stage disease or distant metastases at diagnosis. Systemic treatment options for NEC are limited, with suboptimal efficacy and poor prognosis.
There are currently no therapies specifically approved by regulatory authorities worldwide for EP-NEC. First-line treatment for advanced EP-NEC primarily consists of platinum-based chemotherapy, with an objective response rate (ORR) of approximately 30% to 50% and a median overall survival (mOS) of only around one year. There is no standard treatment following progression on first-line therapy. Second-line treatment options may include oxaliplatin-based FOLFOX, irinotecan-based FOLFIRI, CAPTEM with or without bevacizumab, or temozolomide monotherapy. However, the efficacy of these treatment options remains limited, with an ORR of approximately 10% to 25% and an mOS of approximately eight months. Accordingly, there remains a substantial unmet medical need for patients with advanced EP-NEC, underscoring the urgent need for new and effective treatment options.
About Opamtistomig
Opamtistomig (LBL-024) is emerging as a next-generation pan-cancer backbone therapy with potential overall survival (OS) benefit that simultaneously targets PD-L1 and the co-stimulatory receptor 4-1BB. Currently, opamtistomig is being evaluated in 14 indications, including one pivotal single-arm registrational study, one confirmatory Phase III study, and nine proof-of-concept studies, covering major indications such as NSCLC and multiple cold tumors. To date, opamtistomig has demonstrated robust antitumor activity across seven tumor types—extrapulmonary neuroendocrine carcinoma (EP-NEC), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), biliary tract cancer (BTC), hepatocellular carcinoma (HCC), esophageal squamous cell carcinoma (ESCC), and ovarian cancer (OC)—highlighting its clinical value and broad therapeutic promise.
Developed using Leads Biolabs’ proprietary X-Body bispecific platform, opamtistomig is designed to simultaneously block PD-1/PD-L1 immune suppression and conditionally activate 4-1BB, an agonist pathway, resulting in a potent and synergistic anti-tumor immune response. It has a safety profile comparable to PD-1/PD-L1 inhibitors and demonstrates broader-spectrum anti-cancer potential. Mechanistically, 4-1BB agonism can reactivate exhausted T cells and promote robust T-cell proliferation, offering significant promise for PD-1/PD-L1–resistant or immunologically “cold” tumors and potentially offering durable survival benefits.
Recognizing its clinical potential, opamtistomig received Breakthrough Therapy Designation (BTD) from China’s National Medical Products Administration (NMPA) in October 2024, and Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) in November 2024. Additionally, in January 2026, opamtistomig was granted Fast Track Designation (FTD) by the FDA and ODD by the European Commission, further underscoring its potential to address unmet medical needs in this patient population. In July 2026, its New Drug Application (NDA) was granted priority review designation by the NMPA, followed by NDA acceptance in August 2026, positioning opamtistomig as a potential world’s first approved 4-1BB-targeting antibody, the first approved agonist antibody, and the first approved treatment for EP-NEC.
About Leads Biolabs
Founded in 2012, Leads Biolabs is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies to address underserved medical needs in oncology, autoimmune, and other severe diseases both in China and globally.
Leads Biolabs is a front-runner in next-generation immuno-oncology treatments with a differentiated pipeline of 15 innovative drug candidates, including five clinical-stage drug candidates and one registration-stage asset.
The Company adopts a science-driven R&D approach and has successfully established comprehensive R&D capabilities spanning antibody discovery and engineering, in vivo and in vitro efficacy evaluation, as well as druggability assessment. It has also developed multiple proprietary technology platforms, including LeadsBody (a CD3 T-cell engager platform), X-body (a 4-1BB engager platform), TOPiKinectics (an ADC platform) and ImBiTDC (a TDC platform), which serve as the cornerstone for its continued innovation and have been validated by the clinical outcomes of its bispecific antibody portfolios.
Leads Biolabs has established integrated capabilities across early discovery, translational medicine, clinical development, CMC and business development. The innovative nature and competitive strengths of its drug candidates, coupled with its global perspectives, proactive strategy, and efficient clinical validation, have made it an attractive partner for leading industry players and investment institutions. For more information, please visit https://en.leadsbiolabs.com/
CONTACT: Contact: yizi@leadsbiolabs.com
